Patient Stratification

VitroScan’s proven effective Predictive Tumor Testing Platform is developed for patient stratification to enrich trail populations, thereby improving probability of success, decrease the number of patients per trail, fast track FDA & EMA approval and saving tremendous amounts of costs regularly involved in clinical trials.

VitroScan offers rapid testing of patients tumor tissues (2 weeks turnaround time) to classify the patient’s sensitivity to novel & standard of care cancer therapies. Patient derived tumor tissues are tested for chemotherapy, small molecules, antibodies, ADC’s, immunotherapies. Our proprietary technology pipeline provides accurate ex vivo testing in a preserved tumor microenvironment (TME) and applies image based analysis to identify the treatment sensitive and insensitive patients.

Discuss your clinical trial stratification needs with our expert team.

Home Patient Stratification